The Use of Nanoparticulates to Treat Breast Cancer

Tang, Xin‐Ying; Loc, Welley Siu; Dong, Chuan; Matters, Gail L.; Butler, Peter J.; Kester, Mark; Meyers, Craig; Jiang, Yixing; Adair, James H.

doi:10.2217/nnm-2017-0202

Cited by 88 publications

(55 citation statements)

References 153 publications

(157 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides anti-CD44 monoclonal antibodies, several nano-delivery systems have been developed to target CD44 receptors using different targeting moieties, such as HA [ 168 ]. In recent years, with an in-depth understanding of the molecular biology of BC, a number of promising nano-therapeutic strategies have been developed [ 170 ]. In a study, pegylated PTX nanocrystals (PEG-PTX-NCs) were prepared and the antitumor efficacy of PEG-PTX-NCs was investigated.…”

Section: Application and Clinical Trials Of Nanocarrier-based Thermentioning

confidence: 99%

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Wei

Lau

2020

Cancers

View full text Add to dashboard Cite

Conventional chemotherapy is still an important option of cancer treatment, but it has poor cell selectivity, severe side effects, and drug resistance. Utilizing nanoparticles (NPs) to improve the therapeutic effect of chemotherapeutic drugs has been highlighted in recent years. Nanotechnology dramatically changed the face of oncology by high loading capacity, less toxicity, targeted delivery of drugs, increased uptake to target sites, and optimized pharmacokinetic patterns of traditional drugs. At present, research is being envisaged in the field of novel nano-pharmaceutical design, such as liposome, polymer NPs, bio-NPs, and inorganic NPs, so as to make chemotherapy effective and long-lasting. Till now, a number of studies have been conducted using a wide range of nanocarriers for the treatment of solid tumors including lung, breast, pancreas, brain, and liver. To provide a reference for the further application of chemodrug-loaded nanoformulations, this review gives an overview of the recent development of nanocarriers, and the updated status of their use in the treatment of several solid tumors.

show abstract

Section: Application and Clinical Trials Of Nanocarrier-based Thermentioning

confidence: 99%

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Wei

Lau

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…There are different nanocarriers reported for the generation of ACNPs as novel therapeutics. Among them, inorganic, polymeric ACNPs, and immunoliposomes have been the most evaluated ACNPs in this setting [ 72 ].…”

Section: Acnps For Breast Cancer Therapymentioning

confidence: 99%

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Juan

Cimas

Bravo³

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer is the most common invasive tumor in women and the second leading cause of cancer-related death. Nanomedicine raises high expectations for millions of patients as it can provide better, more efficient, and affordable healthcare, and it has the potential to develop novel therapeutics for the treatment of solid tumors. In this regard, targeted therapies can be encapsulated into nanocarriers, and these nanovehicles are guided to the tumors through conjugation with antibodies—the so-called antibody-conjugated nanoparticles (ACNPs). ACNPs can preserve the chemical structure of drugs, deliver them in a controlled manner, and reduce toxicity. As certain breast cancer subtypes and indications have limited therapeutic options, this field provides hope for the future treatment of patients with difficult to treat breast cancers. In this review, we discuss the application of ACNPs for the treatment of this disease. Given the fact that ACNPs have shown clinical activity in this clinical setting, special emphasis on the role of the nanovehicles and their translation to the clinic is placed on the revision.

show abstract

“…These are colloidal particles having submicron-sized with a therapeutic drug encapsulated within their polymeric matrix or adsorbed or conjugated onto the surface [9,10]. Nanoparticles can be targeted to specific sites by surface modifications, which provide specific biochemical interactions with the receptors expressed on target cells.…”

Section: Nanoparticlesmentioning

confidence: 99%

Improvement of Cancer Therapy by Nanotechnology

Mohanty¹

2017

VIJ

View full text Add to dashboard Cite

Conventional cancer therapy has many drawbacks because of the high drug dose, systemic toxicity and lacking potential targeting output. The applications of nanotechnology for cancer therapy have been shown to overcome the limitation associated with conventional treatments. It plays a pivotal role by delivering cancer drugs in a sustained and targeted manner to the malignant tumour cells, thereby reducing the systemic toxicity of the anticancer drugs. It offers a unique approach and comprehensive technology against cancer therapy through early diagnosis, prediction, prevention, personalized therapy and medicine. This review discussed the various tools of cancer nanotechnology that are presently used in the improvement of cancer therapy.

show abstract

The Use of Nanoparticulates to Treat Breast Cancer

Cited by 88 publications

References 153 publications

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Recent Progress of Nanocarrier-Based Therapy for Solid Malignancies

Antibody Conjugation of Nanoparticles as Therapeutics for Breast Cancer Treatment

Improvement of Cancer Therapy by Nanotechnology

Contact Info

Product

Resources

About